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Abstract 
Objective: Model trajectories of viral load measurements from time of starting 
combination antiretroviral therapy (cART), and use the model to predict whether 
patients will achieve suppressed viral load ( 200 copies/mL) within 6-months of 
starting cART. 
Design: Prospective cohort study including HIV-positive adults (UK Collaborative HIV 
Cohort Study). 
Methods: Eligible patients were antiretroviral-naïve and started cART after 1997. 
Random-effects models were used to estimate viral load trends. Patients were randomly 
selected to form a validation dataset with those remaining used to fit the model. We 
evaluated predictions of suppression using indices of diagnostic test performance. 
Results: Of 9562 eligible patients 6435 were used to fit the model and 3127 for 
validation. Mean log10 viral load trajectories declined rapidly for 2-weeks post-cART, 
moderately between 2-weeks and 3-months, and more slowly thereafter. Higher pre-
treatment viral load predicted steeper declines, whilst older age, white ethnicity and 
boosted-PI/NNRTI-based cART-regimen predicted a steeper decline from 3-months 
onwards. Specificity of predictions and the diagnostic odds-ratio substantially improved 
when predictions were based on viral load measurements up to the 4-month visit 
compared to the 2 or 3-month visits. Diagnostic performance improved when 
suppression was defined by two consecutive suppressed viral loads compared to one. 
Conclusions: Viral load measurements can be used to predict if a patient will be 
suppressed by 6-months post-cART. Graphical presentations of this information could 
help clinicians decide the optimum time to switch treatment regimen during the first 
months of cART.  
Abstract
 Keywords: combination antiretroviral therapy, CD4 cell count, HIV-1, predicted 
virological suppression, treatment switch, viral load 
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Abstract 24 
Objective: Model trajectories of viral load measurements from time of starting combination 25 
antiretroviral therapy (cART), and use the model to predict whether patients will achieve 26 
suppressed viral load ( 200 copies/mL) within 6-months of starting cART. 27 
Design: Prospective cohort study including HIV-positive adults (UK Collaborative HIV 28 
Cohort Study). 29 
Methods: Eligible patients were antiretroviral-naïve and started cART after 1997. Random-30 
effects models were used to estimate viral load trends. Patients were randomly selected to 31 
form a validation dataset with those remaining used to fit the model. We evaluated 32 
predictions of suppression using indices of diagnostic test performance. 33 
Results: Of 9562 eligible patients 6435 were used to fit the model and 3127 for validation. 34 
Mean log10 viral load trajectories declined rapidly for 2-weeks post-cART, moderately 35 
between 2-weeks and 3-months, and more slowly thereafter. Higher pre-treatment viral load 36 
predicted steeper declines, whilst older age, white ethnicity and boosted-PI/NNRTI-based 37 
cART-regimen predicted a steeper decline from 3-months onwards. Specificity of predictions 38 
and the diagnostic odds-ratio substantially improved when predictions were based on viral 39 
load measurements up to the 4-month visit compared to the 2 or 3-month visits. Diagnostic 40 
performance improved when suppression was defined by two consecutive suppressed viral 41 
loads compared to one. 42 
Conclusions: Viral load measurements can be used to predict if a patient will be suppressed 43 
by 6-months post-cART. Graphical presentations of this information could help clinicians 44 
decide the optimum time to switch treatment regimen during the first months of cART.  45 
 46 
Keywords: combination antiretroviral therapy, CD4 cell count, HIV-1, predicted virological 47 
suppression, treatment switch, viral load  48 
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Introduction 49 
Combination antiretroviral therapy (cART) based on 3 antiretroviral drugs from at least two 50 
drug classes slows HIV replication and prevents transmission of HIV.  Factors taken into 51 
consideration when selecting a patient’s first cART-regimen include: the presence/absence of 52 
genotypic resistance against specific antiretroviral drugs; potential side-effects; co-53 
morbidities; drug-interactions and patient preference[1]. Current guidelines recommend 54 
monitoring the effectiveness of first-line cART using routine viral load (VL) measurements 55 
(copies of HIV-1 RNA per millilitre of plasma)[1–3], at about 4-weeks after initiation of 56 
treatment and then every 3-months to confirm undetectable VL levels[1]. 57 
 58 
HIV-dynamic studies have improved our understanding of the process of virus elimination 59 
after initiation of cART[4–5]. During the first few weeks of treatment there is a rapid decline 60 
in VL, primarily due to the decay of productively infected cells[4,6–8]. The rate of decay 61 
becomes slower thereafter due to the release of HIV viruses by macrophages and other long-62 
lived cells of the lymph nodes[4,5,8]. Finally, the decline levels off, probably due to 63 
reservoirs of long-lived cells still producing HIV virus[4]. In some cases the VL level may 64 
rise again, for example because of non-adherence to the cART regimen or emergence of 65 
resistant virus[4]. 66 
 67 
Clinicians may be tempted to increase monitoring or switch drug therapy during the phase of 68 
slow VL decline, even though this is predictable and the patient is likely to achieve viral 69 
suppression. Early treatment switching may be unnecessary and has disadvantages including 70 
that the new regimen may be less effective than the current one, a reduction in the number of 71 
available future treatment options, and the possibility of side-effects associated with the new 72 
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regimen. Conversely, delays in switching regimen after virologic failure has occurred could 73 
result in the accumulation of resistance mutations, immunologic decline and an increased risk 74 
of clinical events. Guidelines recommend that a switch of cART-regimen should be 75 
considered if a patient’s VL fails to fall to undetectable levels (<50 copies/mL) after 24 to 36-76 
weeks of treatment[1,2].  77 
 78 
In this article we model repeated measurements of VL from start of cART to the first 79 
suppressed VL.  Among patients with 2 observed measurements, we use this model to 80 
predict a patient’s future post-cART VL measurements given their observed measurements 81 
up to 2,3 or 4-months post-cART. Based on these future measurements we predict whether 82 
patients will achieve a suppressed VL measurement within 26-weeks of start of cART, test 83 
the reliability of these predictions, and show how this information can be used to enhance 84 
decisions on when to switch first-line cART. 85 
 86 
Methods 87 
Study patients 88 
The UK Collaborative HIV Cohort (UK-CHIC) study was initiated in 2001 and collates 89 
routine data on HIV-positive patients attending some of the largest clinical centres in the UK 90 
since 1st January 1996. The project was approved by a Multicentre Research Ethics 91 
committee and local ethics committees. Patients are included in the study provided they are 92 
HIV-positive, have attended one of the collaborating centres at any time since 1996 and are 93 
aged 16 years or over[9]. Analyses are based on data collected up to 31st December 2012. 94 
 95 
Patients were eligible for analysis if they were antiretroviral-naıve, started cART after 1997, 96 
had at least one CD4 measurement within the period 90-days before to 6-days after starting 97 
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cART, at least one VL measurement within the period 90-days before to 0-days after starting 98 
cART, and at least two post-cART VL measurements observed within the first year of 99 
starting cART, where the first measurement was >200 copies/mL. Suppression was a priori 100 
defined as a single VL 200 copies/mL. 101 
 102 
Statistical analyses 103 
Because we were only concerned with modelling the viral decay phase from start of treatment 104 
to time of first suppression within the first year of cART, VL measurements after time of first 105 
suppression or first year of cART were censored. Patients may stop or switch treatment 106 
regimens due to toxicities, side-effects, suspected treatment nonresponse and other problems. 107 
Because stopping or switching treatment due to suspected treatment nonresponse could have 108 
biased our analyses and reasons for switching were sparsely recorded, we censored VL 109 
measurements after a patient stopped treatment for at least 7-days or switched treatment.  For 110 
a minority of patients their first suppressed VL, included in the analysis, was below the 111 
detection limit and was replaced with the detection limit value. 112 
 113 
VL measurements were 1og10-transformed in order to stabilize the variance and to meet 114 
normality assumptions of the residuals[10]. When modelling the relationship between 1og10-115 
transformed VL and time we considered a fractional-polynomial of one and two degrees with 116 
powers -2, -1, -0.5, 0, 0.5, 1, 2, 3 (power zero is interpreted as a natural-log 117 
transformation)[11] and linear-spline models of one and two knots with the first knot at 2, 4 118 
or 6-weeks and the second knot at 2, 3 or 4-months. We fitted random-effects models with 119 
the intercept and trajectory terms random at the patient-level, thus allowing VL trajectories to 120 
vary between patients. We compared the fractional-polynomials and linear-spline models 121 
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with respect to the Bayesian Information Criterion (BIC) and satisfaction of the model’s 122 
assumptions[12]. 123 
  124 
Patients were classified by their first-line cART-regimen (NNRTI-based, PI-based, boosted-125 
PI, other), pre-treatment CD4 count (<25, 25 to 49, 50 to 99, 100 to 199, 200 to 349, 350 to 126 
499, 500 cells/L) and pre-treatment VL (<10000, 10000 to <100000, 100000 to <500000, 127 
500,000 copies/mL). Patients with >1 measurement within the pre-treatment period were 128 
classified using the measurement closest to the start of cART. 129 
 130 
We included covariates sex, age at start of cART, ethnicity, exposure, type of first-line 131 
cART-regimen, pre-treatment CD4 cell count and pre-treatment VL. For each covariate, 132 
interactions between the covariate and the intercept and trajectory terms were considered. We 133 
compared the BIC statistic of all models with up to 5 interactions.  134 
 135 
Predictions of future VL measurements and the associated prediction error (the measure of 136 
uncertainty about those predictions) depend upon the fixed-effects coefficients and the 137 
variance parameters[13,14]. See Appendix for details about generation of these predictions 138 
and prediction error. 139 
 140 
We validated the prediction model by randomly selecting patients to form a validation 141 
dataset. Because our aim was to predict suppression within the first 6-months of a patient 142 
starting (and continuing on) their first cART-regimen, to form the validation dataset we 143 
randomly selected 40% of those patients who did not switch or stop treatment either before 144 
their first suppressed VL or during the first 6-months since starting cART. The remaining 145 
patients (including those ineligible for random selection) formed the model-fitting dataset. 146 
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 147 
All patients in the model-fitting and validation datasets were used in the analysis to validate 148 
the prediction model. The model-fitting dataset was the training data for our prediction 149 
model. Using this model we predicted future VL measurements for patients of the validation 150 
dataset. For patients in the model-fitting dataset we used all of their observed VL 151 
measurements up to one year post-cART. And, for patients in the validation dataset we 152 
categorized VL measurements within specific clinic visits by rounding the measurement time 153 
to the nearest month (e.g. measurements at 2.7 and 3.12 months were categorized as observed 154 
at the 3-month visit). Observed VL measurements up to and including specified clinic visits 155 
were used to predict future measurements. We only predicted future measurements among 156 
patients who were not censored (due to suppression, treatment switching or dropout) at the 157 
follow-up prior to the time-interval being predicted. 158 
 159 
Based on the predicted future VL trajectories we predicted whether each patient would 160 
achieve suppression (single predicted VL  200 copies/mL) within 6-months of starting 161 
cART. We also classified patients in the validation dataset according to whether they were 162 
observed to achieve suppression (single observed VL  200 copies/mL) within 6-months of 163 
starting cART.  We evaluated prediction of suppression using common indices of diagnostic 164 
test performance: sensitivity, specificity, positive-predictive value, negative-predictive value, 165 
likelihood-ratio of a positive result, likelihood-ratio of a negative result and the diagnostic 166 
odds-ratio (DOR)[15]. We conducted four sensitivity analyses: (1) suppression defined by 167 
two consecutive VL measurements 200 copies/mL, (2) patients of the validation dataset 168 
randomly selected from all eligible patients, (3) VL measurements not censored after a 169 
patient stopped or switched treatment, and (4) among the first suppressed VL measurements 170 
we censored those measurements below the detection limit. 171 
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 172 
Following Taylor, Yu and Sandler[16], we derived prediction-graphs depicting patients’ 173 
predicted VL measurements (with 95% prediction intervals) up to 6-months post-cART, 174 
patients’ observed measurements from previous visits and their measurement from the 175 
current visit. Using this most recent measurement, a new graph can be produced, allowing 176 
real time monitoring of patients’ progression. 177 
 178 
Results 179 
Of 47201 patients included in UK-CHIC up to 31st December 2012, 24135 started cART 180 
before 1998 or before entering the study, or did not start cART. A further 5235 had no CD4 181 
or VL measurements within the specified pre-treatment periods. Of the remaining patients, 182 
1617 were suppressed before start of cART, 519 had zero post-cART VL measurements, 385 183 
had one (unsuppressed) post-cART VL measurement, and for 5748 their first post-cART VL 184 
measurement was suppressed, leaving 9562 eligible for analyses. Table 1 presents patient 185 
characteristics according to pre-treatment VL. Most were men, approximately half were 186 
homosexual or bisexual, of white ethnicity and started on a NNRTI-based cART-regimen. 187 
Compared with patients with pre-treatment VL 10000 copies/mL, a higher proportion of 188 
patients with pre-treatment VL <10000 copies/mL were female, Black African, heterosexual 189 
and started on a boosted-PI cART-regimen. Median pre-treatment CD4 decreased with 190 
increasing pre-treatment VL. 191 
 192 
A total of 7249 (76%) patients achieved at least one suppressed VL measurement within the 193 
first year of cART. Among these, the median time to first suppressed VL measurement was 194 
2.76 [interquartile range (IQR) 1.91–3.91] months and the median number of VL 195 
measurements, up to and including the first suppressed measurement, was 4 [IQR 3–5] 196 
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measurements. Of the 2313 (24%) patients who did not achieve at least one suppressed VL, 197 
the median number of VL measurements was 3 [IQR 2–4].  198 
 199 
Among the 9562 patients eligible for analysis, 1649 (17%) stopped their first-line cART-200 
regimen (for at least 7-days) or switched to a second-line cART-regimen either before their 201 
first suppressed VL or during the first 6-months after starting cART. We randomly selected 202 
3127 (40%) of the remaining 7913 patients to form the validation dataset. The 6435 patients 203 
not randomly selected (including the 1649 ineligible for random selection) formed the model-204 
fitting dataset. Figure 1 shows how the patients eligible for analysis were assigned to the 205 
validation and model-fitting datasets. The patients’ characteristics in the model-fitting 206 
(Appendix-table 2) and validation (Appendix-table 3) datasets were similar. 207 
 208 
  Figure 2 shows mean log10 VL trajectories predicted by the  best fitting model, a linear-209 
spline with knots at 2-weeks and 3-months post-cART, in which mean log10 VL trajectories 210 
varied between patients with different pre-treatment VL group, age at start of cART, ethnic 211 
group and type of first-line cART-regimen. For all patient groups except those with pre-212 
treatment VL <10,000 copies/mL, mean log10 VL trajectories declined rapidly between start 213 
of cART and 2-weeks post-cART, moderately between 2-weeks and 3-months and more 214 
slowly from 3-months onwards. Higher pre-treatment VL predicted a steeper decline in mean 215 
log10 VL for all three phases.  For example, among patients with pre-treatment VL between 216 
10000 and <100000 copies/mL estimated decline in mean log10 VL during phases 1,2 and 3 217 
were respectively 3.58 [95% CI  3.52, 3.65] , 0.39 [95% CI  0.36, 0.41]  and 0.06 [95% CI  218 
0.03, 0.08] log10 copies/mL per month, whilst among patients with pre-treatment VL  219 
≥500000 copies/mL the corresponding declines were 4.46 [95% CI  4.38, 4.54] , 0.56 [95% 220 
CI  0.53, 0.59]  and 0.15 [95% CI  0.12, 0.17] log10 copies/mL per month. For the first and 221 
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second phases there was little difference according to age and ethnic group, and the decline of 222 
mean log10 VL was more gradual for PI-based regimen than for the other cART-regimen 223 
groups. During the third-phase, older age at start of cART predicted a steeper decline, the 224 
decline was steeper for White than non-White patients, and steeper for boosted-PI and 225 
NNRTI-based regimens than for PI-based or other regimens. 226 
 227 
Table 2 compares observed and predicted viral suppression within 6-months of start of cART 228 
among patients in the validation dataset, based on observed VL measurements up to and 229 
including the 2, 3 and 4-month visits. Because predictions were not generated for patients 230 
who were censored on or before the specified visit or who did not have an observed 231 
measurement at the specified visit, the number of patients in the validation dataset decreases 232 
from the 2-month to the 4-month visit. Between the 2 and 4-month visits, specificity of the 233 
predictions substantially improved whilst sensitivity of the predictions slightly decreased.  234 
 Diagnostic accuracy improved substantially, from DOR 5.25 [95% CI 4.09, 6.74] at 2-235 
months to 15.60 [10.77, 22.56] at 4-months. 236 
 237 
Compared to suppression defined by a single VL 200 copies/mL, under the stricter 238 
definition of suppression based on two consecutive VLs 200 copies/mL then, at each 239 
specified visit, the number of patients at risk (i.e. not previously suppressed) was higher and 240 
the percentage of patients observed and predicted to be suppressed was lower (Appendix-241 
table 4). Specificity and negative-predictive value were substantially higher under the stricter 242 
definition of suppression. All indicators of diagnostic performance showed greater accuracy 243 
of predicting suppression when suppression was defined by two consecutive VLs 200 244 
copies/mL compared to a single VL 200 copies/mL. 245 
 246 
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The results of the remaining sensitivity analyses, where: the validation dataset was a random 247 
sample of all patients eligible for analysis (Appendix-table 5), measurements after stopping 248 
or switching treatment were not censored (Appendix-table 6) and first suppressed VLs below 249 
the detection limit were censored (Appendix-table 7), were similar to the results of the main 250 
analysis (Table 2). 251 
 252 
Predicting time to suppression 253 
Figure 3 compares observed with predicted future VL measurements before and after 3-254 
month visit, for patients who were selected to illustrate a range of VL patterns and 255 
predictions. The shaded areas denote 95% prediction intervals for each patient. Because 256 
patients had a small number of observed measurements the prediction intervals were wide.  257 
At the 3-month visit patient-A was not predicted to achieve suppression within 6-months of 258 
starting cART (left-hand graph). The new measurement (labelled +) was better than expected 259 
(below the predicted trajectory) and the updated graph predicted a steeper decline from 3 to 260 
6-months (right-hand graph), although still not predicted to be suppressed by 6-months. 261 
Patient-B was predicted to be suppressed approximately 3-months post-cART (left-hand 262 
graph) and the new measurement agrees with the predicted trajectory, and so very little has 263 
changed in the updated prediction (right-hand graph). Based on these graphs, a clinician may 264 
decide that patients A and B should continue on their first-line cART-regimen, as they are 265 
predicted to decline steadily, and to next measure the patients’ VL at the 5-month visit to 266 
confirm that they have become suppressed. Patient-C was initially predicted to achieve 267 
suppression by 3-months post-cART and patient-D was predicted to steadily decline almost 268 
achieving suppression by 6-months. Their 3-month measurements were worse than expected 269 
(above the predicted trajectory) and the updated graphs show that they were less likely to be 270 
suppressed by 6-months, which is consistent with their future measurements.  For patient-C a 271 
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clinician may decide at the 3-month visit to switch to second-line cART therapy as the 272 
patient’s trajectory is predicted to level off to above 200 copies/mL. For patient-D a clinician 273 
may decide to continue with the first-line cART therapy and to measure the patient’s VL at 4-274 
months post-cART to confirm that the decline has slowed down. The clinician could then 275 
update the prediction-graph using the 4-month measurement and review the decision to 276 
maintain the first-line regimen. 277 
 278 
Discussion 279 
We fitted a flexible linear mixed-effects model to repeated VL measurements from the time 280 
of starting cART, and used this model to predict the effectiveness of the first cART-regimen 281 
in achieving VL suppression based on individual patients’ pre-treatment clinical information 282 
and post-cART VL measurements. Mean log10 VL trajectories declined rapidly between start 283 
of cART and 2-weeks post-cART, moderately between 2-weeks and 3-months and more 284 
slowly thereafter. Higher pre-treatment VL predicted a steeper decline in mean log10 VL for 285 
all three phases. During the third-phase, older age at start of cART predicted a steeper 286 
decline, the decline was steeper for White than non-White patients, and steeper for boosted-287 
PI and NNRTI-based regimens than for PI-based or other regimens. The model’s predictive 288 
ability improved markedly when based on VL measurements up to the 4-month clinic visit 289 
compared to the 2 or 3-month visits. Patients’ current VL trajectory and future VL 290 
predictions can be graphically presented and used to assess if a patient is likely to become 291 
virologically suppressed within 6-months of start of treatment whilst on their current 292 
regimen. 293 
 294 
Among the patients eligible for analysis 60% (5753) had a least one post-cART VL within 295 
the first 2-weeks since starting treatment and so we are confident that our data supports 296 
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estimation of a change in VL within the first 2-weeks. A key feature is that the model predicts 297 
future VL measurements using a series of observed measurements, making efficient use of all 298 
available data. Furthermore, the predictions can be updated as new measures are obtained, 299 
which further improves prediction accuracy.  300 
 301 
This study has several limitations. Patients’ measurements were censored after the first 302 
occurrence of a suppressed VL measurement and so those patients who had a rapid decline in 303 
VL contribute only a few observations to the model. Our model cannot reliably predict 304 
suppression before 3-months post-cART, which occurred among 3187 (33%) of the patients 305 
eligible for inclusion in our analyses. Only a few patients were treated with integrase 306 
inhibitors, which are now more widely used. Our predictions were based on a small number 307 
of observed measurements: the prediction intervals were consequently wide. Some patients 308 
stopped taking treatment or switched to a second-line cART-regimen before their VL 309 
measurements had dropped below 200 copies/mL. Information on reasons for a change in 310 
treatment was not available. We censored all VL measurements that were observed after a 311 
patient stopped or switched treatment and, in a sensitivity analysis, inclusion of these 312 
censored measurements did not change our conclusions. Lastly, patients may have dropped 313 
out of the study due to reasons unrelated to virological response, or because of loss to follow-314 
up or AIDS-related mortality. Random-effects models, as used in this study, are robust to 315 
dropout that is predictable from observed data (‘missing at random’)[17,18] but our estimates 316 
may have been biased by a dropout mechanism that is not predicted by observed VL 317 
measurements.  318 
 319 
Several HIV-dynamic studies, modelling data from start of treatment up to 8 or 12-weeks 320 
post-treatment, have reported a rapid decline in weeks 1 to 3 and a slower decline 321 
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thereafter[19-28]. A HIV-dynamic study with 72-weeks of follow-up reported three phases of 322 
decreasing decay rates, where the transition from phases 1 to 2 was estimated at 16.1 days 323 
and from phases 2 to 3 at 15.7 weeks[29]. A cohort of cART-naïve and cART-experienced 324 
patients, with measurements at 2-weeks, 3, 6 and 9-months, modelled viral decay using a 325 
linear-spline with a single knot at 3-months[30]. 326 
 327 
Our finding that higher pre-treatment VL predicted steeper declines in mean log10 VL is 328 
broadly consistent with the literature[19,21,28,31]. Findings in some studies that trends did 329 
not differ by pre-treatment VL[20], or that higher pre-treatment VL predicted slower decline 330 
during phase-1[22,26], may be explained by differences in the potency of the treatment 331 
regimens and pre-treatment virus clearance-ratios and turnover rates of infected cells[21].  332 
Although a few small studies (<225 patients) reported that VL trends did not differ by age or 333 
ethnicity[19,22,30], our findings that older age predicted steeper declines and that declines 334 
were steeper for White than non-White patients are consistent with reports that older age 335 
predicted a shorter time to suppression[32-37] and that White patients are more likely to 336 
become suppressed than non-Whites[37-43].  In keeping with our results Wu et al[21] 337 
reported a steeper decline for NNRTI-based regimens compared to a PI-based regimen.  338 
 339 
Several studies have reported that declines in VL during weeks 1 to 3 predicted virological 340 
response at 8, 12 and 24-weeks[19,23,24,27] and that VL measurements at 4 and 8-weeks 341 
were strong predictors of virological response at 24-weeks[44,45]. However, our study is the 342 
first of which we are aware to use all available VL measurements to predict first suppression 343 
by 24-weeks. 344 
 345 
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We have shown that frequent VL monitoring can reliably predict by 4-months post-cART if a 346 
patient will be suppressed within 6-months of starting treatment.  Presenting the observed and 347 
future predicted measurements in a graphical plot could aid clinicians in their decision 348 
whether to change cART regimens in patients not suppressed by 3-months post-cART. 349 
Possible actions might include: returning at 6-months post-cART to confirm VL suppression, 350 
returning in 1-month for next VL measurement to minimize any uncertainty, or switch to 351 
second-line therapy. We hope that the information provided in these prediction-graphs will 352 
provide reassurance in making robust decisions regarding future cART-regimens, and avoid 353 
unnecessary changes of regimen. 354 
 355 
In summary, we have shown how a series of VL measurements can be utilized to predict 356 
future VL measurements, and how this information can be presented graphically. Future work 357 
could extend models to allow for informative dropout and develop a web-based tool[46], 358 
where a clinician inputs the information into a web-based calculator and the tool outputs a 359 
prediction-graph. 360 
 361 
  362 
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Table 1. Characteristics of the 9562 eligible patients 
 Pre-treatment HIV-1 RNA (copies/mL) 
 <10kb 10k to <100k 100k to <500k 500k 
Number of patients 756 3372 3825 1609 
Median (IQR)a age (years) 36 (31-42) 37 (31-43) 37 (32-44) 38 (33-45) 
Male % 56 74 79 79 
Risk group   %     
   Homo/bisexual 35 55 61 59 
   IDU 4 2 2 2 
   Heterosexual 55 37 32 35 
   Other/not known 6 5 4 4 
Ethnicity   %      
   White 40 57 61 62 
   Black African 43 27 23 25 
   Other 14 14 14 12 
   Not known 3 2 2 1 
First-line cART-regimen %     
   NNRTI-based 52 63 67 63 
   PI-based 8 5 5 5 
   Boosted-PI 33 27 23 27 
   Other 7 5 5 5 
Median (IQR) pre-treatment HIV-1 
RNA (log10 copies/ml) 
3.43  
(2.86-3.78) 
4.67 
(4.43-4.86) 
5.32  
(5.15-5.50) 
5.88  
(5.71-6.00) 
Median (IQR) pre-treatment CD4 cell 
count (cells/L) 
272 
 (180-400) 
236  
(159-320) 
180  
(84-270) 
114  
(42-218) 
a IQR: Inter-quartile range; b k: A thousand. 
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Table 2. Validation of the model for predicting future suppression by 6 months since start of treatment 
given observations up to a specified visit 
 2-month visit 3-month visit 4-month visit 
No. patients$ 1927 1127 698 
Observed suppressed 81% 69% 51% 
Predicted suppressed 80% 67% 51% 
Sensitivity  [95% CI#] 86% [84%, 88%] 81% [79%, 84%] 80% [76%, 85%] 
Specificity  [95% CI] 46% [41%, 51%] 63% [58%, 68%] 79% [75%, 83%] 
PPV   [95% CI] 87% [85%, 89%] 83% [80%, 86%] 80% [76%, 84%] 
NPV  [95% CI] 44% [39%, 49%] 60% [55%, 65%] 79% [75%, 84%] 
LR+   [95% CI] 1.60 [1.45, 1.76] 2.21 [1.92, 2.55] 3.86 [3.12, 4.78] 
LR–   [95% CI] 0.30 [0.26, 0.36] 0.30 [0.25, 0.35] 0.25 [0.20, 0.31] 
DOR  [95% CI] 5.25 [4.09, 6.74] 7.49 [5.65, 9.93] 15.60 [10.77, 22.56] 
$ Number of patients not suppressed at the specified visit and with at least one future measurement.  
Abbreviations:  CI is confidence interval; PPV is positive predictive value; NPV is negative predictive 
value; LR+ is likelihood ratio of a positive result; LR– is likelihood ratio of a negative result; DOR is 
diagnostic odds-ratio. 
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Fig. 1. A flowchart depicting assignment of the patients eligible for analysis to the validation and model-fitting 
datasets. 
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Fig. 2. Predicted mean log10 HIV-1 RNA trajectories within the first year of starting combination antiretroviral therapy (cART) according to (A) baseline viral load groups, 
(B) age at start of cART, (C) ethnic group and (D) type of cART-regimen. The solid black line in each graph denotes the predicted mean log10 HIV-1 RNA trajectory for the 
reference patient: white male, aged 35 years at start of cART, homosexual or bisexual, first-line cART-regimen includes a NNRTI, pre-treatment CD4 count between 200 and 
349 cells/L and pre-treatment viral load between 100,000 and < 500,000 copies/mL. 
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Fig. 3. Prediction graphs of 4 selected patients based on observations measured before 3-month visit (left-hand 
column) and on observations measured after 3-month visit (right-hand column). The solid line is the patient’s 
predicted log10 HIV-1 RNA trajectory with 95% uncertainty intervals (shaded regions). The dashed line 
indicates the cut-off for suppression (200 copies/mL). 
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Appendix 
We used the parameter estimates from our final random-effects model (Appendix-table 
1) to generate predictions of future viral load (VL) measurements and the associated 
prediction error. Following Taylor and Law, we describe how these predictions were 
generated for patient 𝑖[1].  
 
Suppose patient 𝑖 has 𝑛𝑖 observed VL measurements 𝑌𝑖 = (𝑌𝑖1, ⋯ 𝑌𝑖𝑗 , ⋯ , 𝑌𝑖𝑛𝑖), where 𝑌𝑖𝑗 
is the log10 VL measurement observed at measurement time-point 𝑗. The random-effects 
model is   
𝑌𝑖 = 𝑋𝑖𝛽 + 𝑍𝑖𝑢𝑖 + 𝑒𝑖, 
with fixed-effects coefficients 𝛽 and design matrix 𝑋𝑖, random-effects coefficients 𝑢𝑖 
and design matrix 𝑍𝑖 and level-1 residuals 𝑒𝑖. The random effects 𝑢𝑖 and residuals 𝑒𝑖 are 
independently, normally distributed with zero means and covariances 𝐺 and 𝜎2𝐼𝑛𝑖 . 
 
We wish to predict 𝑛𝑖
𝐹 future log10 VL measurements 𝑌𝑖
𝐹 at pre-specified time-points. 
Let 𝑋𝑖
𝐹and 𝑍𝑖
𝐹denote the fixed-effects and random-effects design matrices 
corresponding to these future time-points. To generate the predictions we require the 
following components: Ω𝑖 = 𝑍𝑖𝐺(𝑍𝑖)
𝑇 + 𝜎2𝐼𝑛𝑖, Λ𝑖 = 𝑍𝑖
𝐹𝐺(𝑍𝑖)
𝑇 and Ω𝑖
𝐹 = 𝑍𝑖
𝐹𝐺(𝑍𝑖
𝐹)𝑇 +
𝜎2𝐼𝑛𝑖
𝐹 . The prediction of future measurements 𝑌𝑖
𝐹given the observed measurements 𝑌𝑖 is 
𝑌𝑖
𝐹 = 𝑋𝑖
𝐹𝛽 + Λ𝑖
𝐹(Ω𝑖)
−1(𝑌𝑖 − 𝑋𝑖𝛽) 
and the prediction error is 
Ω𝑖
𝐹 − Λ𝑖
𝐹(Ω𝑖)
−1(Λ𝑖
𝐹)𝑇 + (𝑋𝑖
𝐹 − Λ𝑖
𝐹(Ω𝑖)
−1𝑋𝑖)𝑣𝑎𝑟(𝛽)(𝑋𝑖
𝐹 − Λ𝑖
𝐹(Ω𝑖)
−1𝑋𝑖)
𝑇,  
Supporting document
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where 𝑣𝑎𝑟(𝛽) represents the covariance matrix of the fixed-effects coefficients 𝛽 and is 
obtained from the fitted random-effects model. 
 
Our approximation for the prediction error accounted for uncertainty in the estimation 
of the fixed effects coefficients and variance parameters, but not the estimation of the 
variances and covariances between the observed and future measurements[1]. Provided 
the sample size is reasonably large then this uncertainty can be ignored[1,2].  
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Appendix-table 1: Coefficients of the final model 
Fixed effects  Estimates reported on the log10 scale  
[95% confidence interval] 
      Reference groupa  Constant  5.11 [5.10, 5.13] 
 Timeb: 0 to 2 weeks -4.18 [-4.24, -4.12] 
 Time: 2 weeks to 3 months -0.49 [-0.51, -0.47] 
 Time: 3 to 12 months -0.10 [-0.08, -0.13] 
   
 Compared to the reference group  
 IDU Constant  0.03 [-0.02, 0.07] 
 Heterosexual Constant -0.01 [-0.03, 0.02]  
 Other risk group Constant  0.01 [-0.03, 0.04] 
    
 CD4c < 25  Constant  0.12 [0.09, 0.15] 
 CD4  25 to 49 Constant  0.11 [0.07, 0.14] 
 CD4  50 to 99 Constant  0.10 [0.08, 0.12]  
 CD4  100 to 199 Constant  0.05 [0.03, 0.07] 
 CD4  350 to 500 Constant -0.02 [-0.04, 0.01] 
 CD4   500 Constant  0.003 [-0.03, 0.04] 
    
 VLd < 10000 Constant -1.48 [-1.51, -1.45] 
  Time: 0 to 2 weeks  1.91 [1.78, 2.04] 
  Time: 2 weeks to 3 months  0.35 [0.31,  0.39] 
  Time: 3 to 12 months -0.02 [-0.06, 0.02] 
    
 VL 10000 to < 100000 Constant -0.60 [-0.62, -0.58] 
  Time: 0 to 2 weeks  0.60 [0.53, 0.67] 
  Time: 2 weeks to 3 months  0.06 [0.03,  0.08] 
  Time: 3 to 12 months  0.04 [0.01, 0.07] 
    
 VL  500000 Constant  0.50 [0.48, 0.52] 
  Time: 0 to 2 weeks -0.32 [-0.41, -0.24] 
  Time: 2 weeks to 3 months -0.08 [-0.11, -0.06] 
  Time: 3 to 12 months -0.05 [-0.09, -0.02] 
    
 Age at start of cART Constant -0.001 [0.00, 0.002] 
  Time: 0 to 2 weeks -0.0004 [-0.004, 0.003] 
  Time: 2 weeks to 3 months -0.003 [-0.004, -0.002] 
  Time: 3 to 12 months -0.001 [-0.002, 0.0005] 
    
 Black African Constant -0.04 [-0.06, -0.01] 
  Time: 0 to 2 weeks -0.06 [-0.13, 0.01] 
  Time: 2 weeks to 3 months  0.09 [0.06,  0.11] 
  Time: 3 to 12 months  0.04 [0.02, 0.07] 
    
 Other ethnicity Constant -0.02 [-0.04, 0.001] 
  Time: 0 to 2 weeks -0.08 [-0.17, 0.004] 
  Time: 2 weeks to 3 months  0.03 [-0.002,  0.06] 
  Time: 3 to 12 months  0.04 [0.004, 0.08] 
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 Appendix-table 1 continued: Coefficients of the final model 
 Fixed effects  Estimates reported on the log10 scale  
[95% confidence interval] 
 Unknown ethnicity Constant -0.01 [-0.06, 0.05] 
  Time: 0 to 2 weeks  0.25 [0.03, 0.47] 
  Time: 2 weeks to 3 months  0.07 [-0.002,  0.14] 
  Time: 3 to 12 months  0.03 [-0.06, 0.11] 
    
 PI-based regimen Constant -0.02 [-0.05, 0.01] 
  Time: 0 to 2 weeks  0.37 [0.22, 0.51] 
  Time: 2 weeks to 3 months  0.09 [0.04,  0.14] 
  Time: 3 to 12 months  0.08 [0.04, 0.12] 
   
 Boosted PI-based  Constant  0.02 [0.002, 0.03] 
 Regimen Time: 0 to 2 weeks  0.31 [0.24, 0.38] 
  Time: 2 weeks to 3 months -0.05 [-0.07, -0.02] 
  Time: 3 to 12 months -0.03 [-0.06, -0.001] 
    
 Other regimen Constant -0.05 [-0.08, -0.02] 
  Time: 0 to 2 weeks  0.22 [0.08, 0.35] 
  Time: 2 weeks to 3 months  0.06 [0.01,  0.10] 
  Time: 3 to 12 months  0.04 [-0.01, 0.09] 
   
      Random effects  Variance or covariance  
[95% confidence interval] 
 Individual level   
                               Constant  0.036 [0.033, 0.039] 
                               0 to 2 weeks  0.624 [0.566, 0.689] 
                               2 weeks to 3 months   0.067 [0.061, 0.073] 
                               3 to 12 months  0.039 [0.034, 0.044] 
                               Constant, 0 to 2 weeks  0.034 [0.024, 0.043] 
                               Constant, 2 weeks to 3 months -0.008 [-0.012, -0.005] 
                               Constant, 3 to 12 months -0.005 [-0.009, -0.001] 
                               0 to 2 weeks, 2 weeks to 3 months  0.041 [0.026, 0.056] 
                               0 to 2 weeks, 3 to 12 months -0.070 [-0.087, -0.054]  
                               2 weeks to 3 months, 3 to 12 months  0.002 [-0.003, 0.006] 
   
 Measurement level   
                                     Constant 0.159 [0.155, 0.162] 
a Reference patient: white male, aged 35 years at start of cART, homosexual or bisexual, first-line cART-
regimen includes a NNRTI, pre-treatment CD4 count between 200 and 349 cells/L and pre-treatment 
viral load between 100,000 and < 500,000 copies/mL. b Time since start of caRT. c Pre-treatment CD4 cell 
count (cells/L). d Pre-treatment viral load (copies/mL). 
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Appendix-table 2.   Characteristics of the 6435 patients from the model-fitting dataset 
 Pre-treatment HIV-1 RNA (copies/mL)  
 <10k 10k to <100k 100k to <500k 500k  
Number of patients 520 2227 2599 1089  
Median (IQR)a age (years) 37 (31-43) 37 (31-43) 37 (32-43) 38 (32-45)  
Male % 56 73 78 79  
Risk group   %      
   Homo/bisexual 34 54 61 59  
   IDU 4 3 2 2  
   Heterosexual 56 38 33 34  
   Other/not known 6 5 4 5  
Ethnicity   %      
   White 40 56 60 62  
   Black African 43 27 23 24  
   Other 14 15 14 13  
   Not known 3 2 2 2  
First-line cART-regimen %      
  NNRTI 54 63 66 63  
  PI 8 6 5 5  
  Boosted-PI 32 26 24 27  
  Other 6 5 5 6  
Median (IQR) pre-treatment  
HIV-1 RNA (log10 
copies/ml) 
3.41  
(2.81-3.79) 
4.67 
(4.43-4.86) 
5.32  
(5.16-5.51) 
5.88  
(5.71-6.01) 
 
Median (IQR) pre-treatment  
CD4 cell count (cells/L) 
270 
 (165-400) 
231  
(150-320) 
180  
(80-268) 
110  
(43-207) 
 
a IQR: Inter-quartile range; b k: A thousand  
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Appendix Table 3. Characteristics of the 3127 patients from the validation dataset. 
 Pre-treatment HIV-1 RNA (copies/mL) 
 <10k 10k to <100k 100k to <500k 500k 
Number of patients 236 1145 1226 520 
Median (IQR)a age (years) 36 (31-41) 36 (31-43) 38 (32-44) 39 (33-45) 
Male % 58 75 82 81 
Risk group   %     
   Homo/bisexual 38 58 63 59 
   IDU 3 2 2 2 
   Heterosexual 51 36 31 36 
   Other/not known 7 5 4 3 
Ethnicity   %     
   White 41 58 61 62 
   Black African 44 28 23 26 
   Other 14 13 15 12 
   Not known 1 1 2 1 
First-line cART-regimen %     
  NNRTI 50 63 69 63 
  PI 6 5 5 5 
  Boosted-PI 36 28 22 28 
  Other 8 4 4 4 
Median (IQR) pre-treatment  
HIV-1 RNA (log10 
copies/ml) 
3.51  
(2.94-3.78) 
4.68 
(4.43-4.87) 
5.31 
(5.15-5.48) 
5.86 
(5.71-5.99) 
Median (IQR) pre-treatment  
CD4 cell count (cells/L) 
276 
(196-391) 
242 
(168-321) 
187 
(90-277) 
122 
(40-242) 
a IQR: Inter-quartile range; b k: A thousand  
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Appendix Table 4. Sensitivity analysis regarding observed and predicted suppression defined respectively by 
two consecutive observed and predicted viral load measurements 200 copies/mL. Validation of the model for 
predicting future suppression by 6 months since start of treatment given observations up to a specified visit. 
 2-month visit 3-month visit 4-month visit 
No. patients$ 2787 2224 1782 
Observed suppressed 57% 51% 43% 
Predicted suppressed 59% 51% 42% 
Sensitivity  [95% CI#] 90% [89%, 92%] 93% [92%, 95%] 96% [94%, 97%] 
Specificity  [95% CI] 82% [80%, 84%] 93% [92%, 95%] 96% [94%, 97%] 
PPV   [95% CI] 87% [85%, 89%] 93% [92%, 95%] 94% [92%, 96%] 
NPV  [95% CI] 86% [84%, 88%] 93% [91%, 94%] 97% [96%, 98%] 
LR+   [95% CI] 5.03 [4.45, 5.68] 13.37 [10.76, 16.61] 21.40 [16.13, 28.39] 
LR–   [95% CI] 0.12 [0.10, 0.14] 0.07 [0.06, 0.09] 0.04 [0.03, 0.06] 
DOR  [95% CI] 42.16 
[33.77, 52.62] 
183.15  
[131.88, 254.36] 
481.66 
 [303.67, 763.98] 
$ Number of patients not suppressed at the specified visit and with at least one future measurement.  
Abbreviations:  CI is confidence interval; PPV is positive predictive value; NPV is negative predictive value; 
LR+ is likelihood ratio of a positive result; LR– is likelihood ratio of a negative result; DOR is diagnostic odds-
ratio. 
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Appendix Table 5. Sensitivity analysis regarding the validation dataset was a random sample of the entire 
analysis dataset. Validation of the model for predicting future suppression by 6 months since start of treatment 
given observations up to a specified visit. 
 2-month visit 3-month visit 4-month visit 
No. patients$ 1486 872 532 
Observed suppressed 78% 67% 49% 
Predicted suppressed 79% 66% 50% 
Sensitivity  [95% CI#] 85% [83%, 87%] 81% [77%, 84%] 77% [72%, 82%] 
Specificity  [95% CI] 45% [39%, 50%] 63% [57%, 69%] 76% [71%, 81%] 
PPV   [95% CI] 84% [82%, 86%] 81% [78%, 85%] 76% [71%, 81%] 
NPV  [95% CI] 47% [41%, 52%] 62% [56%, 67%] 78% [73%, 83%] 
LR+   [95% CI] 1.54 [1.40, 1.71] 2.18 [1.86, 2.54] 3.26 [2.60, 4.08] 
LR–   [95% CI] 0.33 [0.27, 0.39] 0.31 [0.26, 0.37] 0.30 [0.24, 0.38] 
DOR  [95% CI] 4.71 [3.60, 6.18] 7.07 [5.16, 9.69] 10.84 [7.25, 16.20] 
$ Number of patients not suppressed at the specified visit and with at least one future measurement.  
Abbreviations:  CI is confidence interval; PPV is positive predictive value; NPV is negative predictive value; 
LR+ is likelihood ratio of a positive result; LR– is likelihood ratio of a negative result; DOR is diagnostic odds-
ratio. 
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Appendix Table 6. Sensitivity analysis regarding observations were not censored after the end of first-line 
cART. Validation of the model for predicting future suppression by 6 months since start of treatment given 
observations up to a specified visit 
 2-month visit 3-month visit 4-month visit 
No. patients$ 1933 1134 707 
Observed suppressed 81% 68% 50% 
Predicted suppressed 75% 65% 51% 
Sensitivity  [95% CI#] 82% [80%, 83%] 79% [76%, 82%] 79% [75%, 83%] 
Specificity  [95% CI] 52% [47%, 57%] 65% [60%, 70%] 79% [74%, 83%] 
PPV   [95% CI] 88% [86%, 89%] 83% [80%, 86%] 79% [75%, 83%] 
NPV  [95% CI] 41% [36%, 45%] 59% [54%, 64%] 79% [75%, 83%] 
LR+   [95% CI] 1.70 [1.53, 1.90] 2.26 [1.96, 2.62] 3.70 [3.01, 4.55] 
LR–   [95% CI] 0.35 [0.31, 0.41] 0.32 [0.28, 0.38] 0.26 [0.21, 0.33] 
DOR  [95% CI] 4.82 [3.79, 6.12] 7.01 [5.31, 9.25] 14.02 [9.77, 20.13] 
$ Number of patients not suppressed at the specified visit and with at least one future measurement.  
Abbreviations:  CI is confidence interval; PPV is positive predictive value; NPV is negative predictive value; 
LR+ is likelihood ratio of a positive result; LR– is likelihood ratio of a negative result; DOR is diagnostic odds-
ratio. 
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Appendix Table 7: Sensitivity analysis regarding censoring of first suppressed measurements below the 
detection of limit. Validation of the model for predicting future suppression by 6 months since start of treatment 
given observations up to a specified visit 
 2-month visit 3-month visit 4-month visit 
No. patients$ 1237 652 393 
Observed suppressed 77% 61% 40% 
Predicted suppressed 77% 63% 45% 
Sensitivity  [95% CI#] 83% [81%, 86%] 77% [73%, 82%] 78% [71%, 84%] 
Specificity  [95% CI] 46% [40%, 52%] 61% [55%, 67%] 77% [72%, 83%] 
PPV   [95% CI] 84% [81%, 86%] 76% [72%, 80%] 70% [63%, 77%] 
NPV  [95% CI] 44% [39%, 50%] 63% [57%, 69%] 84% [79%, 89%] 
LR+   [95% CI] 1.53 [1.37, 1.71] 1.99 [1.69, 2.35] 3.45 [2.69, 4.44] 
LR–   [95% CI] 0.37 [0.30, 0.45] 0.37 [0.30, 0.45] 0.29 [0.21, 0.39] 
DOR  [95% CI] 4.16 [3.11, 5.55] 5.41 [3.83, 7.64] 12.07 [7.44, 19.59] 
$ Number of patients not suppressed at the specified visit and with at least one future measurement.  
Abbreviations:  CI is confidence interval; PPV is positive predictive value; NPV is negative predictive value; 
LR+ is likelihood ratio of a positive result; LR– is likelihood ratio of a negative result; DOR is diagnostic odds-ratio. 
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may assign this Agreement to any of its affiliates.  This Agreement 
will be binding upon and inure to the benefit of the parties hereto and 
their respective successors and permitted assigns. 
b. Counterparts.  This Agreement may be executed in two or more 
counterparts, each of which shall be deemed an original, but all of 
which together shall constitute one and the same document.  
Facsimile or Portable Document Format (PDF) signatures will be 
deemed original signatures for purposes of this Agreement. 
c. Entire Agreement; Amendment.  This Agreement sets forth the 
entire agreement of the parties on the subject hereof and supersedes 
all previous or contemporaneous oral or written representations or 
agreements relating to the rights and duties provided herein, and may 
not be modified or amended except by written agreement of the 
parties. 
d. Force Majeure.  Neither party shall be liable for any default or 
delay on its part in performing any obligation under this Agreement if 
such default or delay is caused by natural disaster, accident, war, civil 
disorder, strike or any other cause beyond the reasonable control of 
such party.  In the event that either party is prevented by such an 
occurrence or circumstance for a period of more than ninety (90) days 
from fulfilling its obligations under this Agreement, the other party 
may terminate this Agreement upon thirty (30) days’ written notice. 
e. Governing Law.  This Agreement shall be governed in all respects 
according to the laws of the State of New York without giving effect 
to the principles of conflict of law thereof. 
f. Headings.  All headings are for reference purposes only and shall 
not affect the meaning or interpretation of any provision hereof. 
g. Severability.  If any provision of this Agreement is held to be 
illegal, invalid, or unenforceable under the present or future laws, 
then such provision shall be revised by a court of competent 
jurisdiction to be enforceable if permitted under applicable law, and 
otherwise shall be fully severable.  In any event, this Agreement shall 
be construed and enforced as if such illegal, invalid, or unenforceable 
provision had never comprised a part of this Agreement, and the 
remaining provisions of this Agreement shall remain in full force and 
effect and shall not be affected by the illegal, invalid, or 
unenforceable provision or by its severance from this Agreement. 
h. Status of the Parties.  The parties are independent contractors.  
Nothing in this Agreement is intended to or shall be construed to 
constitute or establish any agency, joint venture, partnership or 
fiduciary relationship between the parties, and neither party has the 
right or authority to bind the other party nor shall either party be 
responsible for the acts or omissions of the other. 
i. Waiver; Amendment.  The waiver by either party of or the failure 
by either party to claim a breach of any provision of this Agreement 
shall not be, or be held to be, a waiver of any subsequent breach or 
affect in any way the further effectiveness of any such provision.  No 
term or condition of this Agreement may be waived except by an 
agreement by the parties in writing. 
j. Waiver of Jury Trial.  EACH PARTY HEREBY WAIVES ITS 
RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY 
DISPUTE OR LEGAL PROCEEDING ARISING OUT OF THIS 
AGREEMENT OR THE SUBJECT MATTER HEREOF. 
 
[Signature Page Follows] 
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Schedule A 
This Schedule A must be completed by Author in its entirety.  The Publisher is unable to publish the Work unless 
this Schedule A is completely filled out. 
   
Article Tracking # 
 
   
Article Title (the “Work”) 
 
   
Corresponding Author Name (the “Author”) 
 
   
Copyright Owner’s Name 
 
   
Name of Journal in which Work is to be Published 
 
 
Schedule B 
This Schedule B must be completed by Author in its entirety.  The Publisher is unable to publish the Work unless 
this Schedule B is completely filled out. 
PUBLIC ACCESS POLICY FUNDING DISCLOSURE 
1a.  Please disclose below if you or any other author of the Work has received funding for research on which 
the Work is based from any of the following organizations: 
□  National Institutes of Health (NIH) 
□  Howard Hughes Medical Institute (HHMI) 
 
1b.   If any of the following are selected please complete Item 2.  
 
□  Research Councils UK (RCUK)     
□  Austrian Science Fund (FWF)  
□  World Bank  
□  Wellcome Trust/COAF 
□  World Health Organization (WHO) 
Grantee  
□  World Health Organization (WHO) 
Employee 
□  Bill and Melinda Gates Foundation 
 
2.  If you have selected funding from the above list in 1b., please disclose the Open Access option to which 
the Work will be subject: 
□  Gold route 
□  Green route 
4 
 
NOTE:  If the “Gold” route has been selected, Section 3.b. of the Agreement will apply to the Work, and neither Section 3.a. nor 
Section 3.c. of the Agreement will apply to the Work.  If the “Green” route has been selected, Section 3.c. of the Agreement will 
apply to the Work after an embargo, and neither Section 3.a. nor Section 3.b. of the Agreement will apply to the Work.  
3.  □  This Schedule B is inapplicable to the Work. 
NOTE: If author has selected Item 3, Section 3.a. on the Agreement will apply to the Work, and neither Section 3.b. nor Section 
3.c. of the Agreement will apply to the Work.     
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